Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis

Abstract: Methotrexate (MTX) is one of the mainstays of treatment for several immune-mediated inflammatory joint and skin diseases, especially rheumatoid arthritis (RA) and moderate-to-severe psoriasis. Oral MTX has been used for the treatment of such diseases for decades for many reasons. There is, however, a relevant interpatient variability of clinical and safety outcomes that can also be related to differences in patients’ individual pharmacogenomic profile. Orally administered MTX has been found to have a saturable intestinal absorption and nonlinear pharmacokinetics, with significant consequences on drug bioavailability and clinical efficacy. The current evidence shows that parenterally administered MTX results in rapid and complete absorption, higher serum levels, and less variable exposure than oral dosing. The use of parenteral MTX, particularly when administered as a subcutaneous (SC) injection, has recently raised great interest in order to overcome the limitations of oral MTX. The effectiveness and safety of SC MTX have mostly been assessed in rheumatological settings, especially in patients with RA. There are only a limited number of data on SC MTX in juvenile idiopathic arthritis and even fewer in psoriatic disease. Various clinical experiences have suggested that SC MTX is more effective than oral MTX and may provide significant benefit even in patients in whom oral MTX proved to be inadequate. The increased efficacy of SC MTX resulting from higher drug exposure compared with oral MTX has been associated with a similar safety profile and in various reports even with a lower frequency of gastrointestinal complaints. The aim of this article was to review the available literature data on SC MTX treatment of inflammatory arthritis, with special emphasis on RA and psoriasis, examining differences with oral MTX treatment. A brief mention of pharmacokinetics, pharmacodynamic features and pharmacoeconomic considerations is also given.

Keywords: subcutaneous methotrexate, efficacy, tolerability, juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic disease

Introduction

Methotrexate (MTX), a folic acid reductase inhibitor, is one of the mainstays of treatment for many immune-mediated joint and skin disorders, especially moderate-to-severe psoriasis and rheumatoid arthritis (RA).

MTX is the most common disease-modifying antirheumatic drug (DMARD) employed in daily practice to treat inflammatory arthritis and remains the cornerstone of RA treatment, being capable of decreasing disease activity and radiological progression in a proportion of patients. It is established that prompt diagnosis and a treat-to-target approach can increase the likelihood of inducing sustained remission or low disease activity in active RA. In some patients, this goal can be achieved using MTX as monotherapy or in combination with other traditional DMARDs. The updated recommendations by the European League Against Rheumatism (EULAR) have
corroborated the role of MTX in the therapeutic management of RA defining this drug as an important part of the first-line strategy and the anchor drug in combination therapy with most biological DMARDs.

MTX has traditionally been believed to be less efficacious in psoriatic arthritis (PsA) than RA. In accordance with some authors,7 MTX efficacy may be underrated in PsA owing to the same historical problems encountered in the interpretation of the evidence in RA that are possibly related to the intrinsic and pragmatic limitations of clinical trials rather than to true limitations of MTX effectiveness.

Various clinical trials have investigated the efficacy of MTX in psoriasis, and different MTX-based regimens have been shown to improve the Psoriasis Area and Severity Index (PASI) of at least 75% (PASI75) in up to 40% of patients by week 24.3 A systematic review summarized the real-world evidence on effectiveness of systemic therapies for the treatment of plaque psoriasis in adults.4 In retrospective analysis depicting the real-life setting, treatment with MTX 10–20 mg weekly was found to induce a PASI75 response in 40%–49% of patients at week 12, 62% at week 24, and up to 81% at 1 year. Unfortunately, data from prospective studies are lacking.

Oral MTX has been used in the field of rheumatology and dermatology for decades for several reasons, including efficacy, easy intake, and low cost. However, some patients may require higher doses of oral MTX within the therapeutic range that can be poorly tolerated. It is well known that there is a considerable interpatient variability of clinical and safety outcomes during treatment of various chronic inflammatory diseases with low-dose MTX, which can also be due to differences in patients’ individual pharmacogenomic profile involving drug transport, metabolism, and pharmacodynamic pathways.5,6

These premises have led to scrutiny of the feasibility of parenteral MTX in order to overcome the limitations of oral MTX.7 As a result, the use of parenteral MTX, particularly when given as a subcutaneous (SC) injection, has raised great interest in recent years. The effectiveness and safety of SC MTX have mostly been assessed in rheumatological settings but there are only limited data on psoriasis.

The aim of this manuscript was to review the current evidence on SC MTX treatment of inflammatory arthritis, with special emphasis on RA and psoriasis, examining differences with oral MTX treatment.

Methods of article search and selection
We searched the PubMed database (from January 1, 1990 up to August 31, 2017), using the term “subcutaneous methotrexate” in combination with other pertinent keywords (mainly corresponding to the diseases analyzed), to identify relevant reports, including clinical trials and reviews. Only articles written in English were chosen. They were selected after reading the title and abstract and then the full text was read to evaluate their content. Furthermore, we manually searched articles from the references cited in the retrieved articles. Our objective was to collect a comprehensive number of publications regarding various aspects of SC MTX treatment (eg, pharmacokinetics, pharmacodynamic peculiarities, efficacy, tolerability, and pharmacoeconomic issues). We performed a narrative review instead of a proper meta-analysis in the light of the heterogeneity of data shown by the publications examined (eg, study design, patient populations, drug dosing, study duration, and outcomes).

Clinical data included in this review deal with RA, juvenile idiopathic arthritis (JIA), and psoriatic disease, which are the approved indications for MTX among rheumatic and skin diseases. As most of such reports refer to RA, the selection of articles regarding SC MTX use in RA patients was focused on studies that compared oral and SC formulations or assessed the effect of switching from oral MTX to SC MTX. Information on bioavailability of SC MTX in comparison with the oral route was instead obtained from studies performed in different test subjects, including patients with Crohn’s disease and healthy subjects.

Bioavailability and pharmacokinetics of SC MTX formulation
Orally administered MTX has been found to have a saturable intestinal absorption and nonlinear pharmacokinetics.8,9 These features may have a relevant impact on drug bioavailability and clinical efficacy.

The current evidence shows that parenterally administered MTX results in rapid and complete absorption, higher serum levels, and less variable exposure than oral dosing. No statistically significant differences of the relative bioavailability between SC and intramuscular administration of MTX were detected in six patients with RA.10 Similarly, the equivalence of SC and intramuscular dosing was previously demonstrated in five patients with RA, treated with MTX 12.5–25 mg weekly, who received two treatments at the same dose, 1 week apart, given in a randomly assigned order. In particular, there were no differences in pharmacokinetic parameters (peak concentration, time to reach peak concentration, and area under the time vs concentration curve) for intramuscular and SC injections.11 Given the bioequivalence of the two formulations, the SC route has, therefore, been considered a more convenient and less painful way of administering low-dose MTX.11
Various pharmacokinetic studies (Table 1) consistently demonstrated that SC administration of MTX results in a significantly higher drug bioavailability as compared with the oral route. A meta-analysis has pointed out that, compared with oral administration, treatment of RA with SC MTX is significantly associated with increase in the area under plasma concentration curve from administration to last observed concentration at time t and reduction in the time to reach maximum observed concentration without significant differences in maximum plasma concentration.

Bioavailability of MTX given orally at stable doses of 25 mg/week or more in adults with RA was found to be highly variable and significantly lower than detected with SC MTX, corresponding to approximately two-thirds of that of the SC administration.

A more recent open-label multicenter study recruited RA patients who were treated with different doses of MTX within the therapeutic range used in rheumatology practice (10–25 mg) and found that systemic exposure of oral MTX plateaued at doses ≥15 mg/week. In contrast, SC MTX showed a linear dose-proportional increase in systemic exposure that was greater than oral MTX at each dose and did not plateau over the doses investigated.

Different sites of SC administration (thigh and abdomen) resulted in bioequivalent drug exposure.

Taking into account that SC administration provides dose-proportional and higher drug exposure compared with oral MTX, successful dose-conversion strategies are needed, and a useful method with a convenient dose-conversion table has recently been proposed. However, it is generally recommended that patients should receive the same dose of MTX used for oral administration when switching to SC MTX treatment.

A pilot pharmacokinetic study in only six patients with chronic plaque psoriasis treated with SC or oral MTX (7.5 or 15 mg/week) using dermal microdialysis demonstrated that drug levels and bioavailability of MTX were consistently higher in lesional skin than unaffected skin, without, however, finding a relation with the dose or the route of administration.

Mechanism of action and correlation with the administration route

MTX acts through competitive inhibition of the enzyme dihydrofolate reductase, thus inhibiting purine and thymidine nucleotide synthesis and decreasing the production of DNA and RNA. The anti-inflammatory effects are thought to result from further mechanisms, including modification in cellular redox state, inhibition of polyamines, and accumulation of anti-inflammatory substances, such as adenosine the release of which into the extracellular space is stimulated by MTX.

After MTX enters the cell, there is an enzymatic addition of at least one glutamate residue to the MTX molecule. This process, known as polyglutamation, appears to be relevant for promoting drug intracellular retention and pharmacologic activity, and, in fact, MTX polyglutamate metabolites are

### Table 1 Bioavailability of oral MTX compared with SC MTX

<table>
<thead>
<tr>
<th>References</th>
<th>Sample</th>
<th>MTX weekly dose</th>
<th>Relevant results</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>12 patients with RA</td>
<td>7.5–17.5 mg</td>
<td>Mean relative bioavailability of SC MTX was significantly higher than oral MTX (0.97 vs 0.85)</td>
</tr>
<tr>
<td>12</td>
<td>15 patients with RA</td>
<td>25–40 mg (median, 30 mg)</td>
<td>Mean bioavailability of oral MTX was significantly lower (0.64, range 0.21–0.96) compared with SC MTX</td>
</tr>
<tr>
<td>13</td>
<td>49 RA patients enrolled in an 8-week, open-label, randomized-sequence, three-way crossover trial (47 completed the study)</td>
<td>10, 15, 20, and 25 mg in a random sequence of three treatments: oral, SC into the abdomen, and SC into the thigh</td>
<td>Greater systemic bioavailability of SC MTX at all dose levels (relative bioavailability at 10, 15, 20, and 25 mg was 121%, 114%, 131%, and 141%, respectively, of that seen with oral MTX)</td>
</tr>
<tr>
<td>14</td>
<td>17 patients with JIA</td>
<td>6.1–22.5 mg/m² for oral MTX; 8.8–28.6 mg/m² for SC MTX</td>
<td>Nonlinear pharmacokinetics of oral MTX. In four patients switched from oral to SC MTX at the same dose, the bioavailability of oral MTX was 11%–15% lower as compared with SC MTX</td>
</tr>
<tr>
<td>15</td>
<td>62 healthy subjects recruited in an open-label, randomized, two-sequence, two-period, single-dose, crossover study</td>
<td>Four dose groups (7.5, 15, 22.5, and 30 mg)</td>
<td>Bioavailability was generally higher with SC MTX (injected by prefilled autoinjector pen) compared with oral MTX for all dose groups (higher Cₘₐₓ and AUC₀⁻₉₆ values obtained with SC MTX)</td>
</tr>
<tr>
<td>16</td>
<td>10 patients with stable CD randomized to receive their regular maintenance dose</td>
<td>15–25 mg for 3 weeks</td>
<td>Bioavailability of oral MTX was highly variable and averages 73% of that of SC MTX</td>
</tr>
<tr>
<td>17</td>
<td>11 patients with CD</td>
<td>25 mg for 2 weeks</td>
<td>Mean relative bioavailability of 86% (62%–108%) of oral MTX compared with SC MTX</td>
</tr>
</tbody>
</table>

**Abbreviations:** AUC, area under the plasma-concentration curve; CD, Crohn's disease; Cₘₐₓ, maximum plasma concentration; JIA, juvenile idiopathic arthritis; MTX, methotrexate; RA, rheumatoid arthritis; SC, subcutaneous.
considered the long-lived active compounds. The longer chain polyglutamates (MTXGlu$_{3-4+5}$) have been reported to have the greatest inhibitory potency on the folate pathway enzymes responsible for the pharmacological activity of MTX. Hence, intracellular MTX polyglutamates have been proposed as a potential biomarker of efficacy and toxicity of MTX therapy for inflammatory arthropathies.

In a pharmacokinetic evaluation of 10 RA patients, a switch from oral to parenteral MTX was associated with a selective accumulation of long-chain MTX polyglutamates, consisting in a 37% increase in long-chain and a 132% increase in very long-chain polyglutamates, which was paralleled by a 31% reduction in disease activity.

After assessing red blood cell MTX polyglutamate concentrations in RA patients treated with oral MTX, switching to SC MTX in such patients caused an increase in long-chain polyglutamate levels, which, in turn, showed a significant correlation with decrease in disease activity.

In a cohort of patients with JIA receiving diverse formulations of MTX, there was a great variability in concentrations of MTX polyglutamates, which appeared to be influenced by the route of MTX administration. The route of administration also contributed to the red blood cell concentrations of polyglutamate subtypes. In particular, long-chain polyglutamates (MTXGlu$_{1+2}$), which were the subtypes best correlated with the total intracellular concentration, were more abundant in patients treated with SC MTX, whereas higher concentrations of short-chain MTXGlu$_{1+2}$ were observed in patients receiving oral doses of MTX.

Clinical trials in patients with RA and JIA

The majority of findings regarding the effectiveness and tolerability of SC MTX stem from the assessment of adult patients with RA. Most of the available data suggest that SC MTX is significantly more effective than oral MTX at the same dosage in patients with active RA with no increase in side effects and even with better tolerability outcomes.

It should be emphasized that the study design of many studies precludes a direct comparison of both therapeutic efficacy and drug tolerance between oral and SC formulations.

A meta-analysis based on 7 studies involving 1,335 patients with RA highlighted the superior clinical efficacy of SC MTX over oral MTX, in terms of achievement of the American College of Rheumatology (ACR) criteria for 20% improvement (ACR20) (odds ratio [OR] 1.68; 95% CI 1.09–2.61) and ACR criteria for 70% improvement (ACR70; OR 1.52; 95% CI 1.02–2.26), as well as relief of pain. No significant differences in the ACR criteria for 50% improvement (ACR50) rates were revealed between the two treatment groups. However, the risk of treatment failure was not decreased with SC MTX.

MTX has traditionally been described as a slow-acting drug, with recommendations to evaluate clinical response at least after 12 weeks. However, in the opinion of some researchers, the kinetics of treatment with parenteral MTX appears to be more rapid. Preliminary data showed a prompt effect of optimal initial dosing of SC MTX in patients with early RA, with significant improvement in multiple efficacy parameters seen by 6 weeks, including Clinical Disease Activity Index- and 28-joint Disease Activity Score (DAS28)-based remission.

In light of the pharmacokinetic findings mentioned above, parenteral administration has been recommended when MTX doses $\geq 10–15$ mg/m$^2$ in children with JIA are required.

Similarly, in RA patients, in addition to suggesting SC MTX therapy in case of inadequate response to oral MTX, the SC route might be considered in clinical practice also for doses $>15$ mg.

Efficacy and tolerability data from cohorts of patients with RA and JIA are summarized in the following sections, focusing the attention on results from comparative studies or change in administration route.

Comparative studies with SC MTX vs oral MTX: efficacy data

A limited number of trials have compared oral and SC formulations of MTX in patients with RA or JIA (Table 2), and most of them were open-label observational studies.

The study performed by Braun et al was the first, prospective, randomized, double-blind trial to specifically assess the efficacy outcomes achievable with MTX 15 mg/week given orally or by SC injection in patients with active RA. The primary efficacy end point was the ACR20 at week 24. Patients who did not meet the ACR20 criteria at week 16 were switched from 15 mg oral to SC MTX at the same dose, and from 15 mg SC MTX to 20 mg SC MTX for further 8 weeks. At week 16, 52 subjects were ACR20 nonresponders. SC MTX was found to be significantly more effective than oral administration of the same dosage. Statistically significant differences in the ACR20 and ACR70 response rates in favor of SC MTX were observed at week 24, whereas there was no difference in the proportion of patients achieving an ACR50 response. Patients with a disease duration $\geq 12$ months had even higher ACR20 response rates (89% for SC MTX and 63% for oral MTX).

These results were corroborated by subsequent prospective trials carried out in RA patients.
Table 2 Comparison of efficacy results between oral MTX and SC MTX in patients with RA and JIA

<table>
<thead>
<tr>
<th>References</th>
<th>Study design and patients</th>
<th>Treatment</th>
<th>Efficacy results</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Six-month, multicenter, randomized, DB, double-dummy, controlled, two-arm, Phase IV trial in 384 MTX-naive patients with active RA (DAS28 ≥4); 375 included in the efficacy analysis</td>
<td>15 mg/week of oral MTX (n=187) or SC MTX (n=188) for 24 weeks</td>
<td>At week 24, significantly more patients treated with SC MTX than with oral MTX showed ACR20 (78% vs 70%) and ACR70 (41% vs 33%) responses</td>
</tr>
<tr>
<td>28</td>
<td>Prospective study in 92 patients with active RA</td>
<td>Oral MTX (n=46) or SC MTX (n=46) at equivalent dose for 24 weeks</td>
<td>At 24 week, significant differences in favor of SC MTX in ACR20 and ACR50 response rates (93% vs 80%, and 89% vs 72%, respectively), with similar ACR70 response rates</td>
</tr>
<tr>
<td>29</td>
<td>Multicenter, prospective cohort study to compare oral vs SC MTX over the first year in 666 patients with early RA</td>
<td>Mean weekly dose over first 3 months of 17.2 mg for oral MTX (n=417) and 22.3 mg for SC MTX (n=249)</td>
<td>SC MTX associated with a lower rate of treatment failure (HR 0.55, 95% CI 0.39–0.79) and lower mean DAS28 scores</td>
</tr>
<tr>
<td>30</td>
<td>Retrospective analysis in 411 patients with JIA using the German MTX Registry</td>
<td>Oral MTX (n=259) and SC MTX (n=152) at a similar weekly dose (0.4 mg/kg vs 0.42 mg/kg)</td>
<td>Comparable response according to the ACR Pediatric 30 criteria after 6 months of treatment (73% vs 72%)</td>
</tr>
<tr>
<td>31</td>
<td>Prospective observational study of 55 patients with JIA</td>
<td>Initial median weekly dose of 11.7 mg/m² for oral MTX (n=10) and 14.4 mg/m² for SC MTX (n=45)</td>
<td>No differences in either the rate or the extent of therapeutic response between the two routes</td>
</tr>
</tbody>
</table>

Abbreviations: ACR, American College of Rheumatology; ACR20, ACR criteria for 20% improvement; ACR50, ACR criteria for 50% improvement; ACR70, ACR criteria for 70% improvement; DAS28, 28-joint Disease Activity Score; DB, double blind; HR, hazard ratio; JIA, juvenile idiopathic arthritis; MTX, methotrexate; RA, rheumatoid arthritis; SC, subcutaneous.

Hazlewood et al examined the effectiveness of starting with oral vs SC MTX over the first year in a cohort of 666 patients with early RA (defined by symptoms ≤1 year). Patient who received SC MTX were prescribed a higher dose of MTX as compared with those treated with oral MTX (mean dose over first 3 months was 22.3 vs 17.2 mg/week). At 1 year, treatment change was required in 49% of patients initially treated with SC MTX compared with 77% of those in whom MTX was given orally. After adjusting for potential confounders, SC MTX was associated with a lower rate of treatment failure (hazard ratio [HR] 0.55, 95% CI 0.39–0.79), which in most cases was due to inefficacy. Nevertheless, the result might have been influenced by the higher starting dose used with SC MTX. No significant difference in sustained remission or Health Assessment Questionnaire-Disability Index (HAQ-DI) was instead identified.

However, SC MTX did not prove the superiority over oral MTX in terms of efficacy and tolerability in patients with JIA, as findings obtained in series of such patients were less favorable to SC MTX. In fact, the retrospective analysis performed by Klein et al showed a similar discontinuation rate with oral and SC MTX treatments. In the same way, Fraňová et al described their experience with initial treatment with SC or oral MTX in patients with JIA. More patients received SC MTX, as it was preferentially prescribed in the authors’ own practice. Neither the rate nor the extent of therapeutic response was reported to be influenced by the route of MTX administration, although such findings were not detailed further in the paper.

Switch from oral MTX to SC MTX: efficacy data
Flaring of polyarthritis following substitution of oral for parenteral administration of the same dose of MTX has been reported. Various studies have assessed the response to MTX following a switch to SC treatment in RA or JIA patients with inadequate response to oral MTX (Table 3). These studies were generally retrospective analyses.

An example involving RA patients was the so-called MENTOR study, an observational, retrospective study carried out at the Norfolk and Norwich University Hospital, UK. High continuation rates were seen in patients on SC MTX treatment, leading to a limited requirement of alternative therapeutic strategies including biologic therapy. Only 11.7% of patients previously treated with oral MTX discontinued therapy with SC MTX for any reason during the first year. Data extrapolated from the 2-year cohort indicated that, among patients switched from oral MTX because of inefficacy, only 13.7% failed also with SC MTX and in 11% the addition of biologics was necessary.

In their cohort of RA patients, Mainman et al noted that a high proportion of the patients switching to SC therapy had extreme values of body mass index and many suffered from...
gastroesophageal reflux symptoms which might have contributed to intolerance of oral MTX.\(^{37}\) The authors described an impressive effect of SC MTX in patients who failed to tolerate or respond to oral MTX, as the response to a 6-month SC MTX course was similar to that attainable with biological drugs in three quarters of these patients, leading to potential economic advantages.

In 30 patients who were switched from oral to SC MTX, a decrease in disease activity was associated with increased erythrocyte levels of polyglutamates MTXGlu\(_{3-5}\) (\(P=0.035\)) and MTXGlu\(_{1-3}\) (\(P=0.032\)).\(^{24}\) Likewise, Dervieux et al showed a significant reduction in disease activity in association with a selective accumulation of long-chain MTX polyglutamates in 10 RA patients switched from oral to parenteral MTX.\(^{23}\)

**Tolerability data**

A synopsis of the most relevant tolerability outcomes observed in clinical studies involving patients with RA and JIA is shown in Table 4.\(^{27-31,33,35,38-45}\)

The prospective, randomized, controlled trial carried out by Braun et al demonstrated that SC administration of MTX was significantly more effective than oral administration at the same dosage, without inducing any relevant increase in side effects.\(^{27}\) However, more patients in the SC MTX group (9.3%) than in the oral MTX group (4.3%) prematurely discontinued the study because of adverse events (AEs). The frequencies of moderate-to-severe AEs registered at \(\geq 3\%\) incidence were higher in patients treated with oral MTX. Even the gastrointestinal AEs were comparable between the two formulations. Diarrhea was reported more frequently in patients who received oral MTX and loss of appetite was reported in those belonging to the SC MTX group.

In spite of the greater systemic MTX exposure with SC dosing particularly at dosages \(\geq 15\) mg/week in the pharmacokinetic analysis performed by Schiff et al, the authors likewise revealed no increase in AEs with SC MTX.\(^{13}\)

According to Rutkowska-Sak et al,\(^{45}\) SC administration of MTX has generally been associated with a significant

---

**Table 3 Summary of efficacy results in series of patients with RA and JIA who were changed from oral to SC MTX**

<table>
<thead>
<tr>
<th>References</th>
<th>Study details and patients switched</th>
<th>Reasons for oral MTX failure</th>
<th>Mean weekly MTX dose (mg)</th>
<th>Relevant results obtained with SC MTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>Retrospective study of 196 RA patients</td>
<td>Inefficacy (50.5%), AEs (43.9%), other/unknown (5.6%)</td>
<td>17.7</td>
<td>Persistence of SC MTX therapy in 83% of patients at 1 year, 75.2% at 2 years, and 47.0% at 5 years</td>
</tr>
<tr>
<td>34</td>
<td>Post hoc analysis of 57 patients from the prospective, open-label CAMERA study</td>
<td>AEs (n=21), poor efficacy (n=36)</td>
<td>28±4</td>
<td>Improvement in 63% of patients</td>
</tr>
<tr>
<td>35</td>
<td>Retrospective analysis of 80 RA patients</td>
<td>Gastrointestinal AEs</td>
<td>15.1±5.8</td>
<td>Decrease in DAS28 of 0.3 points ((P&lt;0.05)) after 1 month and of 0.5 points ((P&lt;0.01)) over 4 months</td>
</tr>
<tr>
<td>36</td>
<td>Retrospective study of 103 RA patients</td>
<td>Inefficacy (n=40), intolerance (n=63)</td>
<td>15</td>
<td>Significant decrease of DAS28, ESR, and CRP levels, and pain severity (VAS) after 1 and 3 months</td>
</tr>
<tr>
<td>37</td>
<td>Retrospective study of 78 RA patients</td>
<td>Inefficacy (n=38), AEs (n=40)</td>
<td>20</td>
<td>Significant improvements in DAS28 scores, especially in patients who failed oral MTX therapy due to intolerance</td>
</tr>
<tr>
<td>38</td>
<td>Retrospective study of 50 RA patients</td>
<td>Lack of efficacy (69.6%), AEs (28.2%), or both (2.2%)</td>
<td>14.31</td>
<td>After 6 months, decrease in DAS28 (\geq 1.2) in 74% of cases; “good” or better response according to EULAR criteria in 58% of patients</td>
</tr>
<tr>
<td>39</td>
<td>Retrospective study of 31 JIA patients</td>
<td>Insufficient/no response (n=20), intolerance (n=11)</td>
<td>13.8/m(^2)± 15.4/m(^2)</td>
<td>Lack of efficacy responsible for stopping SC MTX in only three patients</td>
</tr>
<tr>
<td>40</td>
<td>Single-center, questionnaire-based study of unselected JIA patients (switch required in 32 patients)</td>
<td>Intolerance (n=20), reluctance to take oral MTX (n=12)</td>
<td>12.6/m(^2) 12.8/m(^2)</td>
<td>The probabilities of discontinuation after 1, 2, and 3 years of SC MTX treatment are expected to be 6.10%, 8.50%, and 23.20%, respectively</td>
</tr>
</tbody>
</table>

**Notes:** \(^*\)Mean maximum dose. \(^\dagger\)Defined as \(\geq 30\%\) improvement from baseline in three of five variables in the core set, with no more than one of the remaining variables worsening by \(>30\%\).

**Abbreviations:** ACR, American College of Rheumatology; AE, adverse event; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; JIA, juvenile idiopathic arthritis; MTX, methotrexate; RA, rheumatoid arthritis; SC, subcutaneous; VAS, visual analog scale.
A single-dose pharmacokinetic study in healthy subjects detected differences in the safety profile with more gastrointestinal complaints after oral administration than SC dosing (15% vs 28%).

A survey used a questionnaire that was completed by a physician and administered to 70 RA MTX-treated patients (15% vs 28%).

After 2 years, drug discontinuation due to AEs was in 22.2% of patients who did not tolerate oral MTX

Significantly less patients with GI AEs in the first (n=30) and third month (n=27) visits

Discontinuation of SC MTX because of AEs in six patients

Significant reductions were observed in VAS related to frequency and intensity of nausea and frequency of discomfort.

Frequency of vomiting was not significantly reduced

Disappearance of nausea in nine patients (less severe in the other two who continued MTX therapy)

Over 6 months, symptoms of drug intolerance (mostly GI symptoms) in three children

More intense GI AEs with oral MTX (in relation to MTX dose)
intense vomiting. The patients treated with SC MTX had less intense side effects such as nausea and abdominal pain, whereas none of them had vomiting or diarrhea. Intensity of loss of appetite showed no difference between 15 mg oral and SC MTX and was instead higher with 7.5 mg SC MTX than 7.5 mg oral MTX.

A meta-analysis in RA patients showed that SC MTX can significantly reduce the occurrence of nausea (OR 0.53; 95% CI 0.28–0.97) and diarrhea (OR 0.43; 95% CI 0.20–0.95) in comparison with oral MTX, while differences in the development of headache, vomiting, and dyspepsia were not detected. On the other hand, some studies have surprisingly found the prevalence of MTX-induced nausea to be greater in patients receiving parenteral MTX compared with those who took MTX orally.

In an online survey among RA patients who were members of a large arthritis patient community, 382 respondents were naïve for a biologic agent (n=218), SC MTX (n=49), or oral MTX (n=115) in the last 12 months. The patient-reported prevalence of diarrhea was lower among patients treated with SC MTX than among those on oral MTX, while nausea was more frequently reported with SC MTX. The proportions of patients experiencing mental fog and hair loss were higher in patients treated with SC MTX, and this finding was believed to be due to the high drug exposure resulting from SC administration. The frequency and the intensity of pain at the site of injection were significantly lower with SC MTX than with etanercept and adalimumab.

Patil et al explored in depth the nausea and vomiting domains by means of a survey of 49 adolescents and 57 adults with inflammatory arthritis who were using either oral or SC MTX as monotherapy for at least 3 months. Seventy-three percent of adolescents reported nausea compared with 35% of adults (P<0.001). Multiple logistic regression analysis showed that the risk of nausea was significantly associated with being adolescent patients compared with adult patients (OR 6.31, 95% CI 2.38–16.75, P=0.0002), as well as with use of SC MTX (OR 4.49, 95% CI 1.71–11.79, P=0.002) and duration of MTX therapy (OR 3.86, 95% CI 1.00–14.89, P=0.05). Moreover, adolescent patients were estimated to have over six times higher odds of vomiting compared with adult patients.

A high prevalence of MTX-induced gastrointestinal intolerance in JIA has recently been reported by Bulatović et al. MTX intolerance in younger patients has been related to the frequent occurrence of anticipatory and associative complaints in adolescents. Anticipatory nausea is a known psychological adverse effect of MTX that develops through classical conditioning. In the aforementioned survey of Patil et al, 41% of adolescents and 30% of adults experienced anticipatory nausea.

Results obtained from studies in children or adolescents are, therefore, likely to deserve cautious interpretation taking into account the age-related peculiarities seen in this category.

A survey among children and young people with JIA in the UK has revealed that psychosocial health-related quality of life was poorer in patients taking MTX by SC rather than oral route.

**Pharmacoeconomic considerations in rheumatic diseases**

Some retrospective studies have documented relatively high persistence rates of SC MTX treatment, and this, therefore, may minimize or postpone the need to initiate expensive biological therapy. However, there are controversial data from the real-life experience.

For instance, in large cohorts of RA patients from USA administrative databases, the effects of the following three different strategies were examined: increasing the oral MTX dose; adding other traditional DMARDs to oral MTX; or switching from oral MTX to SC MTX. There was no significant difference in the time to initiation of biologic agents between the three treatment strategies. In such cohorts, however, SC MTX therapy seemed to be underutilized and was found to be switched from oral MTX in only 3%–4% of RA patients.

The economic impact of SC MTX or a biologic over a 12-month period was assessed using a decision-based model to define the management of a hypothetical UK population of RA patients who were eligible for biologic therapy after failure of oral treatment with MTX because of intolerance and/or inefficacy. Published data on the continuation rates of SC MTX and biologics were utilized to compare the costs of the two treatment options. The economic model was created on the basis of current National Institute for Health and Clinical Excellence (NICE) guidance and used a cost-minimization methodology from a UK National Health Service (NHS) perspective, taking into account the cost of all drugs and resources. The routine use of SC MTX following oral MTX failure was shown to have the potential to give considerable savings to the NHS. Sensitivity analyses confirmed the robustness of such results. It was, therefore, suggested that patients on oral MTX should undergo a subsequent switch to SC MTX in the case of intolerance or ineffectiveness, before introducing a biologic agent.
Psoriatic disease: clinical and pharmacoeconomic aspects

There are very few data concerning SC MTX treatment in psoriatic disease. Moreover, no study has compared SC and oral routes of administration for the management of psoriasis.

Based on the results of a systematic review of MTX in psoriasis and expert opinion, the initiation of treatment by oral administration is generally preferred. If the efficacy is not sufficient or gastrointestinal tolerance is poor, the use of SC/intramuscular route at the same dosage is suggested. However, if there is a risk of poor compliance, it has been proposed that treatment can be initiated parenterally.

Nevertheless, it is probable that many dermatologists are not yet familiar with the SC route when prescribing MTX.

A survey examining practice preferences of MTX use among Canadian dermatologists and rheumatologists showed that the latter were more likely than dermatologists to switch to a parenteral route and to use SC injections. The majority of dermatologists (97%) and rheumatologists (80%) in everyday practice reported the prescription of oral MTX as the initial treatment. Fewer dermatologists declared to prefer the use of SC MTX as a subsequent switch to parenteral MTX (49% vs 96% of rheumatologists). SC route was chosen as the modality of MTX parental administration by 63% of dermatologists and 98% of rheumatologists.

A questionnaire was completed by 39 Iranian dermatologists who were experts in psoriasis to obtain information on the use of MTX in their clinical practice. Overall, there was a low level of agreement regarding several aspects of MTX dosing and treatment monitoring. Among respondents, 71.8% reported to prescribe MTX as oral route and 28.2% as intramuscular administration, while none chose the SC injection as the usual route of administration.

The most important publication concerning SC MTX in psoriasis refers to the METOP study, an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled, Phase III trial performed at 16 sites in Germany, France, the Netherlands, and the UK. Eligible participants were MTX-naive adults with a diagnosis of plaque-type psoriasis for at least 6 months and suffering from moderate-to-severe disease. A total of 120 patients were randomized according to a 3:1 ratio to receive SC MTX (n=91) or placebo (n=29). The weekly dose of MTX was initially 17.5 mg with possible escalation to 22.5 mg after 8 weeks if patients did not achieve at least a 50% reduction in PASI (PASI50).

The study design consisted of an initial 16-week double-blind phase. From week 16 onward, MTX was administered on an open-label basis to all patients. From week 16 to week 52, patients initially on MTX treatment continued the same dose unless they did not achieve PASI75 with 17.5 mg/week after 24 weeks, and then dose escalation to 22.5 mg was permitted in these cases, while those already treated with a weekly dose of 22.5 mg who were not PASI50 responders at week 24 were withdrawn from the study. Patients belonging to the placebo group were switched to MTX 17.5 mg/week at week 16, with possible change to 22.5 mg at week 24, if PASI50 was not reached.

At week 16, a PASI75 response (primary efficacy end point) was observed in 41% of patients in the MTX group compared with 10% in the placebo group (relative risk 3.93, 95% CI 1.31–11.81; P=0.0026). Response rates increased with continuous MTX treatment. A nonresponder imputation analysis of the modified intent-to-treat population showed that PASI75 response rates at week 52 were 45% in the MTX–MTX group and 34% in the placebo–MTX group. At week 52, PASI improvement ≥90% was seen in almost 28% of patients in each group, and a static physicians’ global assessment score of 0 or 1 (corresponding to a “clear” or “almost clear” disease) was recorded in nearly 40% of patients in both groups. Response of plaque psoriasis was accompanied by significant improvement of concomitant nail psoriasis and health-related quality of life measured by the Dermatology Life Quality Index.

The dropout rate over 52 weeks in patients treated with SC MTX in the METOP study was 39% (n=35/91), with 8 patients discontinuing because of poor efficacy and 19 due to AEs. During the placebo-controlled study phase, gastrointestinal AEs (especially nausea or vomiting) and increases in hepatic enzymes were more common in the MTX group than in the placebo group. Gastrointestinal AEs were usually mild or moderate and led to permanent discontinuation of study drug in 3% of patients who received MTX during the entire study period. Over 52 weeks, elevation of hepatic enzymes...
was reported in 23% of patients started on MTX, with 12% permanently discontinuing treatment.

A biopsy substudy found that the clinical response to SC MTX was correlated to a marked decrease in numbers of skin-infiltrating CD3-positive T cells and CD11c-positive dendritic cells and to downregulation in the cutaneous expression of specific T helper cell type 1 and type 17 cytokines.34

A retrospective study has evaluated 85 patients who were prescribed SC MTX for chronic plaque psoriasis in three dermatology centers in the UK.55 The median number of systemic agents used prior to SC MTX was three, with oral MTX previously used in 82 subjects and subsequently stopped because of ineffectiveness or partial response (n=24) or AEs (nausea n=43, headache n=3, increased liver enzymes n=2, and lethargy n=2). The mean weekly dose of SC MTX was 18.5 mg (range 7.5–30 mg), and treatment duration varied from 2 months to 67 months (mean 14 months). Clinical response was obtained in 59 patients, described as “clear” or “almost clear” in 20 of them. SC MTX was stopped in 10 patients because of inefficacy (n=5), nausea (n=4), and injection site reaction (n=1).

Another multicenter retrospective study showed a high adherence rate after 6 months of treatment with SC MTX in 103 patients with plaque-type psoriasis, most of whom previously treated with other systemic nonbiologic therapies, including oral MTX.56 As regards efficacy, the same study showed that 47% of patients achieved PASI75 at 6 months, and 87% of patients who switched from oral MTX due to inefficacy were still on treatment after 6 months of SC MTX, with a PASI75 response observed in 38% of such patients.

A pharmacoeconomic analysis was carried out in Spain starting from the premises of superior efficacy of SC MTX in RA.3 It has recognized that the additional cost related to the use of the SC route would be counterbalanced by better effectiveness. Moreover, the results of an incremental cost-effectiveness analysis of SC MTX and several alternatives based on data from comparative clinical trials suggested that SC MTX has a higher incremental cost-effectiveness ratio to ciclosporin, adalimumab, and infliximab in the treatment of moderate-to-severe psoriasis.3

Discussion

Current evidence indicates that SC administration of MTX is characterized by linear and predictable pharmacokinetics resulting in higher bioavailability as compared with oral MTX, especially with weekly doses of ≥15 mg.10,12–17 These findings have been found to be paralleled by an improved pharmacodynamic profile related to an enhanced intracellular polyglutamation.23,24

Various clinical experiences, mostly concerning RA patients, give evidence that SC MTX is more effective than oral MTX and may induce significant benefit even in patients in whom oral MTX proved to be inadequate. The increased efficacy of SC MTX resulting from higher drug exposure compared with oral MTX has been associated with a similar safety profile and in various reports even with a lower frequency of gastrointestinal complaints.

It should be stressed that the study design of many studies does not allow a direct comparison of the efficacy and tolerability profiles between oral and SC formulations of MTX. Moreover, the majority of comparative studies were open labeled, and most of the studies examining patients who were changed from oral to SC MTX were retrospective.

The prospective, randomized, double-blind, controlled trial carried out by Braun et al demonstrated that SC administration of MTX was significantly more effective than oral administration at the same dosage, without any relevant increase in side effects.27 The authors observed statistically significant differences in the ACR20 and ACR70 response in favor of SC MTX, with even better ACR20 response rates among patients with a disease duration ≥12 months. The gastrointestinal AEs were found to be similar between the two formulations.

The cumulative evidence on RA has been summarized in a recent meta-analysis the outcomes of which showed that SC MTX can significantly improve the ACR20 and ACR70 responses and the pain severity, and reduce the occurrence of nausea and diarrhea compared with oral MTX.18 However, the two formulations were not significantly different in terms of occurrence of headache, vomiting, and dyspepsia, as well as risk of treatment failure.

Preliminary data suggest the possibility of high persistence rates and optimal adherence with SC MTX.33,38 This may minimize or delay the need to start more expensive alternative therapies, having a considerable economic impact.

Therefore, in RA patients refractory to oral MTX, switching to parenteral administration has been recommended as a useful strategy before introducing other therapies.57,58

There are only a limited number of data on the efficacy and tolerability of SC MTX in JIA, which appear to be more controversial than those available for RA, and even fewer in psoriatic disease.

Conclusion

SC MTX appears an interesting and valid therapeutic option for inflammatory arthritis and psoriatic disease. Also, SC administration may overcome some limitations of oral MTX therapy. It entails optimization of MTX treatment, improving
outcomes and compliance with relevant pharmacoeconomic implications.

However, large randomized trials with low risk of bias due to the study design and methodology are required to draw definite conclusions.

Acknowledgment
The authors thank Mundipharma Pharmaceuticals Srl, Italy, for the editorial support.

Disclosure
GAV served as a speaker and/or advisory board member for Novartis, AbbVie, MSD, Pfizer, and LEO Pharma. NC served as a scientific consultant and/or speaker for Novartis, AbbVie, LEO Pharma, MSD, and Pfizer. FI received personal fees from Actelion, Celgene, Janssen, Pfizer, AbbVie, UCB, and MSD outside the submitted work. The authors report no other conflicts of interest in this work.

References
2. Pincus T, Bergman MJ, Yazici Y. Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in particular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? Clin Exp Rheumatol. 2015;33(Suppl 93):S82–S89.


35. Borman P, Demir G, Kaygusuz F, Okumuş M. LETTER TO THE EDITOR Subcutaneous (SC) methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effects. *Open Rheumatol J*. 2014;8:18–19.


